Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genolair vs Xolair PK/PD study
NCT06494345Phase 1Completed
- Sponsor
- Generium
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omalizumab in allergic asthma (3 arms), sponsored by Generium. Primary endpoints: Peak Plasma Concentration at Day 85 and Area under the plasma concentration versus time curve at Day 85. Started Jan 2023; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT06494345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494345.